Recommended Topic Related To:

Advair Diskus

"The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary di"...

Advair Diskus

Advair Diskus Side Effects Center

Medical Editor: Melissa Conrad Stöppler, MD

Advair Diskus (fluticasone and salmeterol oral inhaler) is a combination of inhaled drugs that is used to treat asthma and chronic bronchitis, including COPD associated with chronic bronchitis. Advair Diskus is used in patients whose symptoms are not adequately controlled on a long-term asthma control medication, since one of the active ingredients in salmeterol is LABA, which has been linked to asthma-related deaths. Advair Diskus should not be used to treat acute episodes of asthma or COPD. Advair Diskus is available in generic form and preparations/dosage of fluticasone propionate/salmeterol (100/50, 250/50, and 500/50).

Side effects of Advair Diskus include upper respiratory tract infections, headaches, nausea, vomiting, diarrhea, mouth or throat yeast infections, and musculoskeletal pain. Drug interactions include MAOI (monoamine oxidase inhibitors) and tricyclic antidepressant drugs. There have not been adequate studies of salmeterol in pregnant women. Fluticasone and salmeterol use by pregnant women should be avoided unless the potential benefit justifies the potential unknown risk to the fetus. Advair Diskus is secreted in breast milk.

Our Advair Diskus Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Advair Diskus in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • bronchospasm (wheezing, chest tightness, trouble breathing);
  • fast or uneven heart beats, restless feeling, tremor;
  • fever, chills, stabbing chest pain, cough with yellow or green mucus;
  • blurred vision, eye pain, or seeing halos around lights;
  • white patches or sores inside your mouth or on your lips; or
  • worsening asthma symptoms.

Less serious side effects include:

  • headache, dizziness;
  • nausea, vomiting, diarrhea;
  • dry mouth, nose, or throat;
  • stuffy nose, sinus pain, cough, sore throat; or
  • hoarseness or deepened voice.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Advair Diskus (Fluticasone Propionate) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Advair Diskus Overview - Patient Information: Side Effects

SIDE EFFECTS: Hoarseness, throat irritation, headache, or stomach upset may occur. If any of these effects persist or worsen, tell your doctor promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and get medical help right away.

Tell your doctor right away if any of these unlikely but serious side effects occur: white patches on tongue/in mouth, signs of infection (such as fever, persistent sore throat), mental/mood changes (such as nervousness), trouble sleeping, vision problems (such as blurred vision), increased thirst/urination, muscle cramps, shaking (tremors).

Get medical help right away if any of these rare but serious side effects occur: chest pain, fast/irregular heartbeat, severe dizziness, fainting, seizures.

A very serious allergic reaction to this product is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Advair Diskus (Fluticasone Propionate)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Advair Diskus FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Long-acting beta2-adrenergic agonists, such as salmeterol one of the active ingredients in ADVAIR DISKUS (fluticasone propionate) , increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of salmeterol (SEREVENT Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol [see WARNINGS AND PRECAUTIONS]. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients.

Systemic and local corticosteroid use may result in the following:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Asthma

Adult and Adolescent Patients Aged 12 Years and Older

The incidence of adverse reactions associated with ADVAIR DISKUS (fluticasone propionate) in Table 2 is based upon 2 placebo-controlled, 12­week, US clinical studies (Studies 1 and 2). A total of 705 adolescent and adult patients (349 females and 356 males) previously treated with salmeterol or inhaled corticosteroids were treated twice daily with ADVAIR DISKUS (100/50- or 250/50-mcg doses), fluticasone propionate inhalation powder (100- or 250-mcg doses), salmeterol inhalation powder 50 mcg, or placebo. The average duration of exposure was 60 to 79 days in the active treatment groups compared with 42 days in the placebo group.

Table 2: Adverse Reactions With ≥ 3% Incidence With ADVAIR DISKUS (fluticasone propionate) in Adult and Adolescent Patients With Asthma

Adverse Event ADVAIR DISKUS (fluticasone propionate)
100/50
(N = 92)
%
ADVAIR DISKUS (fluticasone propionate)
250/50
(N = 84) %
Fluticasone Propionate
100 mcg
(N = 90) %
Fluticasone Propionate
250 mcg
(N = 84)
%
Salmeterol
50 mcg
(N = 180)
%
Placebo
(N = 175)
%
Ear, nose, & throat
  Upper respiratory tract infection 27 21 29 25 19 14
  Pharyngitis 13 10 7 12 8 6
  Upper respiratory inflammation 7 6 7 8 8 5
  Sinusitis 4 5 6 1 3 4
  Hoarseness/dysphonia 5 2 2 4 < 1 < 1
  Oral candidiasis 1 4 2 2 0 0
Lower respiratory
  Viral respiratory infections 4 4 4 10 6 3
  Bronchitis 2 8 1 2 2 2
  Cough 3 6 0 0 3 2
Neurology
  Headaches 12 13 14 8 10 7
Gastrointestinal
  Nausea & vomiting 4 6 3 4 1 1
  Gastrointestinal discomfort & pain 4 1 0 2 1 1
  Diarrhea 4 2 2 2 1 1
  Viral gastrointestinal infections 3 0 3 1 2 2
Non-site specific
  Candidiasis unspecified site 3 0 1 4 0 1
Musculoskeletal
  Musculoskeletal pain 4 2 1 5 3 3

The types of adverse reactions and events reported in Study 3, a 28-week, non-US clinical study of 503 patients previously treated with inhaled corticosteroids who were treated twice daily with ADVAIR DISKUS 500/50, fluticasone propionate inhalation powder 500 mcg and salmeterol inhalation powder 50 mcg used concurrently, or fluticasone propionate inhalation powder 500 mcg, were similar to those reported in Table 2.

Additional Adverse Reactions

Other adverse reactions not previously listed, whether considered drug-related or not by the investigators, that were reported more frequently by patients with asthma treated with ADVAIR DISKUS (fluticasone propionate) compared with patients treated with placebo include the following: lymphatic signs and symptoms; muscle injuries; fractures; wounds and lacerations; contusions and hematomas; ear signs and symptoms; nasal signs and symptoms; nasal sinus disorders; keratitis and conjunctivitis; dental discomfort and pain; gastrointestinal signs and symptoms; oral ulcerations; oral discomfort and pain; lower respiratory signs and symptoms; pneumonia; muscle stiffness, tightness, and rigidity; bone and cartilage disorders; sleep disorders; compressed nerve syndromes; viral infections; pain; chest symptoms; fluid retention; bacterial infections; unusual taste; viral skin infections; skin flakiness and acquired ichthyosis; disorders of sweat and sebum.

Pediatric Patients Aged 4 to 11 Years

The safety data for pediatric patients aged 4 to 11 years is based upon 1 US trial of 12 weeks' treatment duration. A total of 203 patients (74 females and 129 males) who were receiving inhaled corticosteroids at study entry were randomized to either ADVAIR DISKUS 100/50 or fluticasone propionate inhalation powder 100 mcg twice daily. Common adverse reactions ( ≥ 3% and greater than placebo) seen in the pediatric patients but not reported in the adult and adolescent clinical trials include: throat irritation and ear, nose, and throat infections.

Laboratory Test Abnormalities

Elevation of hepatic enzymes was reported in ≥ 1% of patients in clinical trials. The elevations were transient and did not lead to discontinuation from the studies. In addition, there were no clinically relevant changes noted in glucose or potassium.

Clinical Trials Experience in Chronic Obstructive Pulmonary Disease

Short-Term (6 Months to 1 Year) Trials

The short-term safety data are based on exposure to ADVAIR DISKUS (fluticasone propionate) 250/50 twice daily in one 6-month and two 1-year clinical trials. In the 6-month trial, a total of 723 adult patients (266 females and 457 males) were treated twice daily with ADVAIR DISKUS 250/50, fluticasone propionate inhalation powder 250 mcg, salmeterol inhalation powder, or placebo. The mean age of the patients was 64, and the majority (93%) was Caucasian. In this trial, 70% of the patients treated with ADVAIR DISKUS (fluticasone propionate) reported an adverse reaction compared with 64% on placebo. The average duration of exposure to ADVAIR DISKUS (fluticasone propionate) 250/50 was 141.3 days compared with 131.6 days for placebo. The incidence of adverse reactions in the 6-month study is shown in Table 3.

Table 3: Overall Adverse Reactions  With ≥ 3% Incidence With ADVAIR DISKUS (fluticasone propionate) 250/50 in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Adverse Event ADVAIR
DISK US
250/50
(N = 178)
%
Fluticasone
Propionate
250 mcg
(N = 183)
%
Salmeterol
50 mcg
(N = 177)
%
Placebo
(N = 185)
%
Ear, nose, & throat
  Candidiasis mouth/throat 10 6 3 1
  Throat irritation 8 5 4 7
  Hoarseness/dysphonia 5 3 < 1 0
  Sinusitis 3 8 5 3
Lower respiratory
  Viral respiratory infections 6 4 3 3
Neurology
  Headaches 16 11 10 12
  Dizziness 4 < 1 3 2
Non-site specific
  Fever 4 3 0 3
  Malaise & fatigue 3 2 2 3
Musculoskeletal
  Musculoskeletal pain 9 8 12 9
  Muscle cramps & spasms 3 3 1 1

In the two 1-year studies, ADVAIR DISKUS (fluticasone propionate) 250/50 was compared with salmeterol in 1,579 patients (863 males and 716 females). The mean age of the patients was 65, and the majority (94%) was Caucasian. To be enrolled, all of the patients had to have had a COPD exacerbation in the previous 12 months. In this trial, 88% of the patients treated with ADVAIR DISKUS (fluticasone propionate) and 86% of the patients treated with salmeterol reported an adverse event. The most common events that occurred with a frequency of > 5% and more frequently in the patients treated with ADVAIR DISKUS (fluticasone propionate) were nasopharyngitis, upper respiratory tract infection, nasal congestion, back pain, sinusitis, dizziness, nausea, pneumonia, candidiasis, and dysphonia. Overall, 55 (7%) of the patients treated with ADVAIR DISKUS (fluticasone propionate) and 25 (3%) of the patients treated with salmeterol developed pneumonia.

The incidence of pneumonia was higher in patients over 65 years of age, 9% in the patients treated with ADVAIR DISKUS (fluticasone propionate) compared with 4% in the patients treated with ADVAIR DISKUS (fluticasone propionate) less than 65 years of age. In the patients treated with salmeterol, the incidence of pneumonia was the same (3%) in both age-groups. [See WARNINGS AND PRECAUTIONS, Use in Specific Populations.]

Long-Term (3-Year) Trial

The safety of ADVAIR DISKUS (fluticasone propionate) 500/50 was evaluated in a randomized, double-blind, placebo-controlled, multicenter, international, 3-year study in 6,184 adult patients with COPD (4,684 males and 1,500 females). The mean age of the patients was 65, and the majority (82%) was Caucasian. The distribution of adverse events was similar to that seen in the 1-year trials with ADVAIR DISKUS (fluticasone propionate) 250/50. In addition, pneumonia was reported in a significantly increased number of patients treated with ADVAIR DISKUS 500/50 and fluticasone propionate 500 mcg (16% and 14%, respectively) compared with patients treated with salmeterol 50 mcg or placebo (11% and 9%, respectively). When adjusted for time on treatment, the rates of pneumonia were 84 and 88 events per 1,000 treatment-years in the groups treated with fluticasone propionate 500 mcg and with ADVAIR DISKUS (fluticasone propionate) 500/50, respectively, compared with 52 events per 1,000 treatment-years in the salmeterol and placebo groups. Similar to what was seen in the 1-year studies with ADVAIR DISKUS (fluticasone propionate) 250/50, the incidence of pneumonia was higher in patients over 65 years of age (18% with ADVAIR DISKUS (fluticasone propionate) 500/50 vs. 10% with placebo) compared with patients less than 65 years of age (14% with ADVAIR DISKUS (fluticasone propionate) 500/50 vs. 8% with placebo). [See WARNINGS AND PRECAUTIONS, Use in Specific Populations.]

Additional Adverse Reactions

Other adverse reactions not previously listed, whether considered drug-related or not by the investigators, that were reported more frequently by patients with COPD treated with ADVAIR DISKUS (fluticasone propionate) compared with patients treated with placebo include the following: syncope; ear, nose, and throat infections; ear signs and symptoms; laryngitis; nasal congestion/blockage; nasal sinus disorders; pharyngitis/throat infection; hypothyroidism; dry eyes; eye infections; gastrointestinal signs and symptoms; oral lesions; abnormal liver function tests; bacterial infections; edema and swelling; viral infections.

Laboratory Abnormalities

There were no clinically relevant changes in these trials. Specifically, no increased reporting of neutrophilia or changes in glucose or potassium was noted.

Postmarketing Experience

In addition to adverse events reported from clinical trials, the following events have been identified during worldwide use of any formulation of ADVAIR, fluticasone propionate, and/or salmeterol regardless of indication. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to ADVAIR DISKUS, fluticasone propionate, and/or salmeterol or a combination of these factors.

Cardiac Disorders

Arrhythmias (including atrial fibrillation, extrasystoles, supraventricular tachycardia), ventricular tachycardia.

Endocrine Disorders

Cushing syndrome, Cushingoid features, growth velocity reduction in children/adolescents, hypercorticism.

Eye Disorders

Glaucoma.

Gastrointestinal Disorders

Abdominal pain, dyspepsia, xerostomia.

Immune System Disorders

Immediate and delayed hypersensitivity reaction (including very rare anaphylactic reaction). Very rare anaphylactic reaction in patients with severe milk protein allergy.

Metabolic and Nutrition Disorders

Hyperglycemia, weight gain.

Musculoskeletal, Connective Tissue, and Bone Disorders

Arthralgia, cramps, myositis, osteoporosis.

Nervous System Disorders

Paresthesia, restlessness.

Psychiatric Disorders

Agitation, aggression, depression. Behavioral changes, including hyperactivity and irritability, have been reported very rarely and primarily in children.

Reproductive System and Breast Disorders

Dysmenorrhea.

Respiratory, Thoracic, and Mediastinal Disorders

Chest congestion; chest tightness; dyspnea; facial and oropharyngeal edema, immediate bronchospasm; paradoxical bronchospasm; tracheitis; wheezing; reports of upper respiratory symptoms of laryngeal spasm, irritation, or swelling such as stridor or choking.

Skin and Subcutaneous Tissue Disorders

Ecchymoses, photodermatitis.

Vascular Disorders

Pallor.

Read the entire FDA prescribing information for Advair Diskus (Fluticasone Propionate) »

A A A

Advair Diskus - User Reviews

Advair Diskus User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Advair Diskus sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.